Crossmark

The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain

Crossref DOI link: https://doi.org/10.1016/j.oftale.2016.12.006

Published Print: 2017-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Navarro-Navarro, A.

Salom, D.

Martínez-Toldos, J.J.

Udaondo, P.

Fernández-Martínez, C.

Gutiérrez-Arias, L.

Hervás, A.

Rodrigo, R.
License Information

Text and Data Mining valid from 2017-05-01
More Information

This article is maintained by: Elsevier

Article Title: The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain

Journal Title: Archivos de la Sociedad Española de Oftalmología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.oftale.2016.12.006

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.oftal.2016.12.010

Content Type: simple-article

Copyright: © 2017 Sociedad Española de Oftalmología. Published by Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below